Gan & Lee Pharmaceuticals.

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
48.65 ^CNY	+0.41%		-3.49%	-7.60%

04-24	Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-24	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals..

June 13, 2023

Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals. (SHSE:603087) on June 14, 2023. Endogenix generated a revenue of RUB 4.6 million last year.

Pharmaktiv completed the acquisition of remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals. (SHSE:603087) on June 14, 2023.

Latest news about Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023	04-24	CI
Gan & Lee Pharma's Insulin Product Gets Registration Approval in Bolivia	01-26	MT
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug	12-12	MT
Gan & Lee Pharmaceuticals' Unit Gets Nod to Test GZR18 Tablets	12-04	MT
Gan & Lee Pharmaceuticals. announced that it has received CNY 773.151876 million in funding	11-09	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
Gan & Lee Pharma’s Insulin Analogs Gain EU Regulatory Approval	12/10/23	MT
Gan & Lee Pharmaceuticals.(XSSC:603087) added to S&P Global BMI Index	18/09/23	CI
Gan & Lee Pharmaceuticals.(XSSC:603087) added to FTSE All-World Index	18/09/23	CI
Gan & Lee Pharma Advances Trial of New Insulin Product	13/09/23	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2023	18/08/23	CI
Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1023 Injection	20/07/23	MT
Gan & Lee Pharmaceuticals Gets Regulatory Nod for Private Placement	20/06/23	MT
Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals..	13/06/23	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
FDA Accepts Gan & Lee Pharma's Application for Insulin Glargine Injection	24/02/23	MT
Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from S&P Global BMI Index	19/12/22	CI
Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from FTSE All-World Index	12/12/22	CI
Gan & Lee Pharmaceuticals' Insulin Injection Enters Pakistani Market	09/12/22	MT
Gan & Lee Pharmaceuticals.(SHSE:603087) dropped from Shanghai Stock Exchange 180 Value Index	09/12/22	CI
Gan & Lee Pharmaceuticals.(SHSE:603087) dropped from SSE 180 Index	09/12/22	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
Gan & Lee Pharma Co-Founder to Buy $111 Million More Shares; Shares Up Nearly 6%	25/10/22	MT

Chart Gan & Lee Pharmaceuticals.

Duration

Period

More charts

Company Profile

Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Gan & Lee Pharmaceuticals.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

48.45 CNY

Average target price

62.5 CNY

Spread / Average Target

+29.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
GAN & LEE PHARMACEUTICALS.	-7.60%	3.96B
CSL LIMITED	-2.32%	92.59B
SAMSUNG BIOLOGICS CO.,LTD.	+3.16%	41.43B
BIOGEN INC.	-11.77%	33.49B
BIOMARIN PHARMACEUTICAL INC.	-20.45%	14.62B
INCYTE CORPORATION	-9.64%	12.77B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.58B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.00%	11.35B
SWEDISH ORPHAN BIOVITRUM AB	+3.82%	8.97B
INNOVENT BIOLOGICS, INC.	-6.32%	8.3B

Biopharmaceuticals

Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

Pharmaceuticals

Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals..

EPS Revisions